Last updated: September 4, 2026
Voxelotor’s commercial trajectory ended abruptly in 2024. The drug, marketed as Oxbryta by Pfizer, reached approximately $328 million in 2023 revenue after Pfizer acquired Global Blood Therapeutics for about $5.4 billion in 2022. Pfizer withdrew Oxbryta globally in September 2024 after clinical data indicated increased mortality and vaso-occlusive events in patients with sickle cell disease. The withdrawal eliminated near-term sales growth, created a multibillion-dollar impairment, and removed voxelotor from the active treatment market [1]-[4].
What is voxelotor and how was Oxbryta positioned in sickle cell disease?
Voxelotor is an oral hemoglobin S polymerization inhibitor developed to increase hemoglobin oxygen affinity and reduce sickling. Unlike hydroxyurea, which reduces sickling partly through increased fetal hemoglobin, voxelotor was designed to act directly on hemoglobin S polymerization.
The FDA approved Oxbryta in November 2019 for adults and adolescents aged 12 years and older with sickle cell disease. In December 2021, the FDA expanded the indication to children aged four through 11 years [1].
| Attribute |
Voxelotor/Oxbryta |
| Active ingredient |
Voxelotor |
| Initial FDA approval |
November 25, 2019 |
| Initial indication |
Sickle cell disease in patients age 12 and older |
| Pediatric expansion |
December 2021, patients age four and older |
| Route |
Oral |
| Primary commercial company |
Global Blood Therapeutics, then Pfizer |
| Therapeutic category |
Sickle cell disease, hemoglobin S polymerization inhibitor |
| U.S. regulatory status |
Voluntarily withdrawn in 2024 |
| Biosimilar relevance |
None; voxelotor is a small molecule |
Voxelotor was positioned as a disease-modifying oral therapy rather than a supportive treatment. Its commercial value depended on improving anemia and hemolysis without requiring transfusion, hospitalization, or chronic infusion therapy.
How did voxelotor sales develop before withdrawal?
Oxbryta sales grew rapidly after launch, supported by expansion into pediatric patients, increased physician awareness, and the limited number of disease-modifying sickle cell therapies.
Reported net product revenue was approximately:
| Year |
Company |
Oxbryta or voxelotor revenue |
Market context |
| 2020 |
Global Blood Therapeutics |
Approximately $35 million |
First full commercial year was affected by the COVID-19 pandemic |
| 2021 |
Global Blood Therapeutics |
Approximately $195 million |
Broader specialist adoption and reimbursement expansion |
| 2022 |
Global Blood Therapeutics |
Approximately $280 million |
Continued pre-acquisition growth |
| 2023 |
Pfizer |
Approximately $328 million |
First full year under Pfizer ownership |
| 2024 |
Pfizer |
Commercial activity ended in September |
Withdrawal halted sales and distribution |
Global Blood’s revenue growth made voxelotor one of the most commercially important emerging sickle cell products before Pfizer’s acquisition. The company reported strong prescription and patient growth in the years preceding the transaction [2].
Pfizer paid $68.50 per Global Blood share in an all-cash transaction announced in August 2022 and completed in October 2022. The transaction value was approximately $5.4 billion, including assumed debt and other adjustments [3].
Why did Pfizer acquire Global Blood Therapeutics?
Pfizer acquired Global Blood to obtain a commercial sickle cell franchise centered on Oxbryta and to expand its presence in rare hematologic diseases. Pfizer also acquired Global Blood’s development programs and commercial infrastructure.
The transaction thesis relied on several factors:
- Oxbryta had already reached commercial approval.
- The sickle cell population was large relative to many rare-disease markets.
- Treatment duration was expected to be chronic.
- Pediatric expansion increased the addressable population.
- Voxelotor had potential use across additional hemoglobinopathy settings.
- Pfizer could apply global commercialization and reimbursement resources.
The purchase price implied a substantial premium to Global Blood’s unaffected market capitalization. The deal also reflected expectations that Oxbryta could generate materially higher revenue than its pre-acquisition sales base.
The acquisition became financially unfavorable after the FDA safety action. Pfizer recorded an approximately $4.6 billion charge related to the withdrawal and impairment of Oxbryta assets in 2024 [4].
When was Oxbryta withdrawn from the market?
Pfizer announced on September 25, 2024, that it would voluntarily withdraw Oxbryta from all markets and discontinue clinical trials and expanded-access programs. Pfizer also instructed patients and healthcare professionals to stop initiating treatment and to discuss alternative therapy [5].
The decision followed an analysis showing an imbalance in deaths and vaso-occlusive crises among patients receiving voxelotor. The FDA stated that available data suggested the risks outweighed the benefits of continuing treatment [1].
FDA regulatory timeline
| Date |
Regulatory event |
| November 2019 |
FDA approves Oxbryta for sickle cell disease in patients age 12 and older |
| December 2021 |
FDA expands approval to patients age four and older |
| August 2022 |
Pfizer agrees to acquire Global Blood Therapeutics |
| October 2022 |
Pfizer completes acquisition |
| September 2024 |
Pfizer announces worldwide voluntary withdrawal |
| September 2024 onward |
Distribution, clinical trials, and expanded-access supply discontinued |
The withdrawal was a commercial termination rather than a routine loss of exclusivity. Patent life and regulatory exclusivity became economically irrelevant once Pfizer removed the product from the market.
How large was the financial impact of the withdrawal?
The withdrawal affected revenue, intangible assets, inventory, development spending, and the strategic rationale for the Global Blood acquisition.
The principal financial consequences were:
- Immediate loss of Oxbryta revenue.
- Write-off or impairment of acquired intangible assets.
- Disposal of inventory and withdrawal-related costs.
- Termination of clinical development and expanded-access activities.
- Loss of expected future cash flow from chronic sickle cell treatment.
- Reduced return on Pfizer’s approximately $5.4 billion acquisition investment.
At its 2023 revenue level, Oxbryta generated about $328 million annually. That amount was modest relative to Pfizer’s total revenue but significant for a single rare-disease asset. The value destruction was driven by the loss of anticipated long-term revenue, not simply by the loss of one year’s sales.
Estimated commercial trajectory
| Period |
Commercial trajectory |
| 2019-2020 |
Launch phase with limited initial penetration |
| 2021 |
Rapid growth after broader market adoption |
| 2022 |
Continued growth before Pfizer acquisition |
| 2023 |
Approximately $328 million in revenue under Pfizer |
| 2024 |
Abrupt discontinuation following safety concerns |
| 2025 onward |
No legitimate commercial growth case for Oxbryta in the withdrawn indication |
The key financial lesson is that a rare-disease product with strong sales growth can still have a fragile valuation when its safety profile depends on long-term exposure in a medically vulnerable population.
What competitive drugs affected voxelotor’s market position?
Voxelotor competed in a sickle cell treatment market with several therapies serving different clinical objectives.
| Product |
Active ingredient |
Company |
Primary role |
| Oxbryta |
Voxelotor |
Pfizer |
Increased hemoglobin oxygen affinity; withdrawn |
| Hydroxyurea |
Hydroxyurea |
Multiple manufacturers |
Reduces vaso-occlusive complications and increases fetal hemoglobin |
| Adakveo |
Crizanlizumab |
Novartis |
Reduces adhesion-related vaso-occlusive crises |
| Endari |
L-glutamine |
Emmaus Life Sciences |
Reduces complications associated with sickle cell disease |
| Casgevy |
Exagamglogene autotemcel |
Vertex/CRISPR Therapeutics |
Gene-edited therapy for eligible patients |
| Lyfgenia |
Lovotibeglogene autotemcel |
Bluebird bio |
Gene therapy for eligible patients |
Voxelotor’s strongest commercial distinction was oral chronic administration and its focus on anemia and hemolysis. Hydroxyurea remained the broadest established disease-modifying therapy. Crizanlizumab competed more directly on vaso-occlusive crisis reduction, although its own commercial performance faced market and clinical challenges.
Casgevy and Lyfgenia operate in a different segment because they are high-cost, potentially one-time gene therapies requiring specialized treatment centers. They do not represent direct generic substitution for voxelotor, but they compete for treatment budgets and specialist attention.
What happened to voxelotor’s patent and exclusivity position?
Voxelotor was protected by composition-of-matter, formulation, and method-of-use intellectual property. Those rights could have delayed generic competition beyond the statutory five-year new chemical entity exclusivity period that followed the 2019 approval.
The FDA’s approval granted Oxbryta five years of new chemical entity exclusivity, subject to the standard statutory framework. Pediatric exclusivity associated with the later expansion could have added six months to applicable exclusivity periods. The commercial value of those rights ended after the product withdrawal.
Patent risk after withdrawal
A generic manufacturer could still evaluate:
- Abbreviated New Drug Application eligibility.
- Orange Book patent certifications.
- Paragraph IV challenges.
- Formulation or dosage-form workarounds.
- Manufacturing process differences.
- Potential use in non-withdrawn or investigational settings.
The practical market incentive is limited. A generic applicant typically requires a viable prescription market, stable clinical demand, and a regulatory pathway with sufficient commercial return. Pfizer’s withdrawal sharply reduced those incentives.
What was the Orange Book status of Oxbryta?
Oxbryta was approved under NDA 213137 for tablets. Pfizer also obtained approval for an oral suspension formulation under a separate NDA. The FDA Orange Book historically listed patents associated with approved voxelotor products and their formulations.
Because the product was withdrawn for safety reasons, Orange Book listings and patent expiry dates no longer determine the principal market outcome. A withdrawn product can retain listed patents, but patent protection cannot restore commercial demand or offset a regulatory safety action.
The relevant distinction is:
- Patent expiry creates an opportunity for lawful competition.
- Product withdrawal removes the economic target for that competition.
- A generic launch would still require FDA approval and a marketable, legally supportable indication.
Were there Paragraph IV challenges to voxelotor?
Publicly disclosed Paragraph IV litigation did not become a material commercial event before Pfizer’s withdrawal. The product’s market life was too short for patent litigation to become the central determinant of entry timing.
The principal market risk shifted from patent challenge to regulatory discontinuation. This changed the competitive question from “When can a generic launch?” to “Is there a viable product to launch?”
No biosimilar pathway applies because voxelotor is a small-molecule drug. Any future generic would proceed through an ANDA rather than a biosimilar application under the Public Health Service Act.
What manufacturing and intellectual-property barriers affected voxelotor?
Voxelotor manufacturing required control of active pharmaceutical ingredient purity, solid-state properties, formulation performance, and tablet or suspension consistency. These issues could create technical barriers even after composition patents expire.
Potential barriers included:
- Reproducible synthesis of the active ingredient.
- Control of impurities and degradation products.
- Bioequivalence for tablets and oral suspension.
- Formulation stability.
- Pediatric dosing and administration requirements.
- Demonstration of acceptable labeling after the safety withdrawal.
The withdrawal created a separate barrier: regulatory risk. A future sponsor would need a defensible benefit-risk rationale, not merely an equivalent manufacturing process.
Which companies were positioned to challenge or replace Oxbryta?
No company emerged as a direct commercial successor to voxelotor after Pfizer withdrew it. Competitive pressure came from established therapies and emerging disease-modifying approaches.
Established competitors
Hydroxyurea remained the most broadly used pharmacologic comparator. Crizanlizumab targeted vaso-occlusive crises, while L-glutamine addressed complications through a different mechanism.
Curative-intent competitors
Casgevy and Lyfgenia targeted eligible patients with severe disease and access to specialized treatment centers. Their high treatment costs, conditioning requirements, and eligibility constraints limited direct substitution but increased pressure on chronic oral therapies.
Pipeline competition
Other agents under development focused on fetal hemoglobin induction, anti-adhesion mechanisms, inflammation, red-cell biology, and gene therapy. These programs competed for the same specialist population and reimbursement resources.
What generic launch scenarios exist for voxelotor?
The realistic generic scenarios are limited.
| Scenario |
Commercial probability |
Rationale |
| Immediate generic launch after withdrawal |
Low |
No active commercial market and unresolved safety perception |
| Generic development for the original indication |
Low |
Requires substantial regulatory and liability justification |
| Reformulated or restricted-use product |
Low to moderate |
Would require a new benefit-risk rationale |
| Reintroduction by Pfizer |
Very low |
Pfizer discontinued supply and clinical programs |
| Academic or government-sponsored revival |
Low |
Requires new clinical evidence and a sponsor willing to assume risk |
Patent expiration alone would not create a credible launch opportunity. Any future development would depend on new evidence addressing mortality and vaso-occlusive risk.
How strong was the voxelotor patent estate?
The voxelotor patent estate was commercially strong before the withdrawal because it combined an approved active ingredient with formulation and use protections and a five-year new chemical entity exclusivity period. Its weakness was not primarily patent-related. The decisive exposure was clinical and regulatory.
Patent strength can be assessed across four dimensions:
| Dimension |
Assessment |
| Composition protection |
Strong during the protected period |
| Formulation protection |
Meaningful for tablets and pediatric suspension |
| Method-of-use protection |
Potentially valuable but dependent on approved labeling |
| Commercial durability |
Eliminated by the 2024 safety withdrawal |
The estate therefore had legal value but no continuing commercial value after Pfizer stopped distribution.
What is the revenue exposure for Pfizer and the sickle cell market?
Pfizer’s direct annual revenue exposure was approximately $328 million based on 2023 Oxbryta sales. The broader economic exposure was substantially larger because Pfizer paid approximately $5.4 billion for Global Blood and expected future growth beyond the pre-acquisition revenue base.
The withdrawal affected:
- Pfizer’s rare-disease revenue forecasts.
- The value of the Global Blood acquisition.
- Sickle cell treatment choices for patients previously using Oxbryta.
- Specialty pharmacy and distribution arrangements.
- Clinical trial investments.
- Investor expectations for Pfizer’s business-development strategy.
For the sickle cell market, the withdrawal reduced the number of oral disease-modifying options and increased dependence on hydroxyurea, transfusion strategies, supportive care, and high-cost gene therapies.
Key Takeaways
- Voxelotor was FDA-approved in 2019 and expanded to younger pediatric patients in 2021.
- Oxbryta revenue increased to approximately $328 million in 2023.
- Pfizer acquired Global Blood Therapeutics for approximately $5.4 billion in 2022.
- Pfizer withdrew Oxbryta globally in September 2024 after safety data showed increased mortality and vaso-occlusive events.
- Pfizer recorded an approximately $4.6 billion charge associated with the withdrawal and asset impairment.
- Patent protection and Orange Book status became secondary after commercial distribution ended.
- Voxelotor is a small molecule, so biosimilar competition does not apply.
- Generic entry is commercially unlikely without a new safety and efficacy rationale.
- Hydroxyurea, crizanlizumab, L-glutamine, and gene therapies remain the principal competitive alternatives.
- The central risk was clinical-regulatory failure, not ordinary patent expiration.
FAQs
Is voxelotor still available in the United States?
No. Pfizer voluntarily withdrew Oxbryta from the U.S. and other markets in September 2024 and discontinued distribution.
Did Pfizer lose money on the Oxbryta acquisition?
Yes. Pfizer paid approximately $5.4 billion to acquire Global Blood Therapeutics and later recorded an approximately $4.6 billion charge related to Oxbryta withdrawal and impairment.
Can a generic company launch voxelotor after Pfizer’s withdrawal?
A generic company could theoretically pursue an ANDA, but commercial launch is unlikely without a viable market and a satisfactory regulatory explanation for the safety risks.
Is voxelotor a biologic or a small-molecule drug?
Voxelotor is a small-molecule drug. Any future generic would use the ANDA pathway, not the biosimilar pathway.
Which sickle cell drugs replaced Oxbryta?
No single drug replaced Oxbryta. Treatment shifted toward hydroxyurea, crizanlizumab, L-glutamine, transfusion-based care, and gene therapies such as Casgevy and Lyfgenia, depending on patient eligibility and treatment goals.
References
-
U.S. Food and Drug Administration. (2024). FDA alerts patients and health care professionals about voluntary withdrawal of Oxbryta (voxelotor) from the market due to safety concerns. https://www.fda.gov/
-
Global Blood Therapeutics, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.
-
Pfizer Inc. (2022). Pfizer to acquire Global Blood Therapeutics, expanding its leadership in sickle cell disease. https://www.pfizer.com/
-
Pfizer Inc. (2025). 2024 annual report. https://www.pfizer.com/
-
Pfizer Inc. (2024, September 25). Pfizer voluntarily withdraws Oxbryta globally and discontinues all voxelotor clinical trials. https://www.pfizer.com/
